The vaccine against the chikungunya do Butantan Institute and the company Valneva was Approved for application in Brazil . The approval was given on Monday (14) by the National Health Surveillance Agency (Anvisa). The immunizer is authorized to be applied to the population over 18 years.
The vaccine was tested in the United States in 4,000 volunteers aged 18 to 65. The immunizer presented a good security and high immunity profile. Thus, 98.9% of participants produced neutralizing antibodies that remained at least six months.
This immunizer had already received the approval of Food and Drug Administration (FDA), the United States Regulatory Agency, and the European Union’s European Medicines Agency (EMA).
The countries with the most records of the disease are Brazil, Paraguay, Argentina and Bolivia.
This is the first vaccine produced against chikungunya, which can cause chronic joint pain and has already affected 620,000 people worldwide in 2024 alone. Anvisa’s favorable opinion indicates an important step in approving the immunizer’s butantan version, which is under review by the regulatory agency.
According to the São Paulo government, the two vaccines have practically the same composition.
In a clinical study with Brazilian adolescents, published in The Lancet Infectious Diseases in September 2024, after a dose of the vaccine, the presence of neutralizing antibodies was observed in 100% of volunteers with previous infection and 98.8% of those without previous contact with the virus.
Protection against the virus was maintained in 99.1% of young people after six months. The side effects recorded after vaccination were light and moderate, the main headache, body pain, fatigue and fever.
What are the next steps of the Butantan vaccine?
The institute is working in a version with part of the process being carried out in Brazil. Immunizer modifications use national components, and will be better suitable for incorporation by the Unified Health System (SUS). The analysis is pending by Conitec, National Immunization Program and other health authorities.
This new vaccine is considered innovative because it is first first approved based on antibody production. Traditionally, immunizers are approved with studies that prove the effectiveness, comparing the incidence of cases among vaccinated and non -vaccinated people.
*Under supervision
This content was originally published in Anvisa approves Butantan and Valneva Institute vaccine against chikungunya on the CNN Brazil website.
Source: CNN Brasil
I’m James Harper, a highly experienced and accomplished news writer for World Stock Market. I have been writing in the Politics section of the website for over five years, providing readers with up-to-date and insightful information about current events in politics. My work is widely read and respected by many industry professionals as well as laymen.
